1 / 17

Less Until None : A Plan for a World without T1D

Less Until None : A Plan for a World without T1D. JDRF’s Vision for the Future. LESS. UNTIL. NONE. 2. Mission: Less Until None. LESS. UNTIL. NONE. Burden. LESS. Invasive. LESS. Complexity. LESS. Danger. LESS UNTIL NONE. Delivery of Continuous Therapeutic Improvements.

sereno
Télécharger la présentation

Less Until None : A Plan for a World without T1D

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Less Until None:A Planfor a World without T1D

  2. JDRF’s Vision for the Future LESS UNTIL NONE 2

  3. Mission: Less Until None LESS UNTIL NONE Burden LESS Invasive LESS Complexity LESS Danger LESS UNTIL NONE

  4. Delivery of Continuous Therapeutic Improvements Glycemic Control Safety Normal Physiology Restored Therapies Cure Side-Effects Complications Patient Burden Better Safety, Fewer Side-Effects, Less Exposure to Complications

  5. DiscoveryResearch ClinicalDevelopment Deliveryto Patients RESEARCH ADVOCACY RESEARCH ADVOCACY RESEARCH ADVOCACY Regulatory $ $$$ $$$$ $$

  6. DiscoveryResearch ClinicalDevelopment Deliveryto Patients RESEARCH ADVOCACY RESEARCH ADVOCACY RESEARCH ADVOCACY Regulatory $ $$$ $$$$ $$ Investment Investment

  7. Artificial Pancreas Treat-to-Range Artificial Pancreas Multihormone Artificial Pancreas Low Glucose Suspend Artificial Pancreas Treat-to-Target Control Glucose Responsive Insulin Complications Comprehensive Prevention Therapy Complications Predictive Diagnosis Prevention Primary: Vaccine Complications Diabetic Eye Disease Insulin Pumps Infusion Encapsulation Implantable Islets Prevention Secondary Prevention Regeneration Near Term Medium Term Long Term This timeline is based on clinical delivery goals of identified therapies and will be updated as progress is achieved

  8. Artificial Pancreas Automated technologies to help maintain better control of blood-glucose levels Integrated smart technology to automate routine elements of insulin management FDA released final guidance on pathway for commercialization of devices

  9. Glucose Responsive Insulin (GRI) Form of insulin that activated when blood-glucose levels start to rise Simplifies life for and improves overall blood-glucose controls JDRF competition underway to accelerate progress on GRI

  10. Encapsulation Easily implantable Beta cells or islets surrounded by a protective shield/capsule Able to sense glucose levels and produce insulin as needed Hidden from the immune system to sustain normal function Eliminating the need for immunosuppressive drug therapy

  11. Regeneration Ability to create new insulin producing cells destroyed by autoimmune attack Creating abundant supply of Beta cells through stem cells and regeneration Immune therapy for suspected “triggers” including viruses

  12. Secondary Prevention Preserve beta cell function in these newly diagnosed individuals Approaches include: Reducing inflammation Boosting beta cell survival Suppressing the autoimmune attack

  13. Primary Prevention Prevent the autoimmune attack on beta cells before it starts Approaches include: Viral vaccines Beta Cell Autoantigen Vaccines

  14. Funding Scaleand Scope R&DExpertise IndustryInfluence Government Advocacy

  15. Funding Scaleand Scope R&DExpertise IndustryInfluence Government Advocacy

  16. More =Less LESS UNTIL NONE Funding Funding Funding $$$ T1D Funding Funding Funding Funding $$$ $$$ Funding Funding

  17. Thank you!

More Related